Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain

References

• Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7(4):322–337.
   Web of Science ®Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–727.
   PubMed Web of Science ®Google Scholar
• Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. World J Gastroenterol. 2014;20:11525–11537.
   PubMed Web of Science ®Google Scholar
• Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm Bowel Dis. 2011;17:831–848.
   PubMed Web of Science ®Google Scholar
• Martin TD, Chan SSM, Hart AR. Environmental factors in the relapse and recurrence of inflammatory bowel disease: a review of the literature. Dig Dis Sci. 2015;60:1396–1405.
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–1517.
   PubMed Web of Science ®Google Scholar
• Ye Y, Pang Z, Chen W, et al. The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med. 2015;8:22529–22542.
   PubMed Web of Science ®Google Scholar
• López-Serrano P, Pérez-Calle JL, Carrera-Alonso E, et al. Epidemiologic study on the current incidence of inflammatory bowel disease in Madrid. Rev Española Enfermedades Dig Organo of La Soc Española Patol Dig. 2009;101:768–772.
   PubMed Web of Science ®Google Scholar
• Calkins BM, Mendeloff AI. Epidemiology of inflammatory bowel disease. Epidemiol Rev. 1986;8:60–91.
   PubMed Web of Science ®Google Scholar
• Kostić M, Djakovic L, Šujić R, et al. Inflammatory bowel diseases (Crohn´s disease and ulcerative colitis): cost of treatment in Serbia and the implications. Appl Health Econ Health Policy. 2017;15:85–93.
   PubMed Web of Science ®Google Scholar
• Gomollón F, García-López S, Sicilia B, et al. Guía clínica GETECCU del tratamiento de la colitis ulcerosa elaborada con la metodología GRADE. Gastroenterol Hepatol. 2013;36:e1–e47.
   PubMedGoogle Scholar
• Jess T, Gamborg M, Munkholm P, et al. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol. 2007;102:609–617.
   PubMed Web of Science ®Google Scholar
• López Bastida J, Oliva J, Antoñanzas F, et al. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. Gac Sanit. 2010;24:154–170.
   PubMed Web of Science ®Google Scholar
• Sacristán JA, Oliva J, Del Llano J, et al. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit. 2002;16:334–343.
   PubMedGoogle Scholar
• Vallejo-Torres L, García-Lorenzo B, García-Pérez L, et al. Informes de Evaluación de Tecnologías Sanitarias: valor de un Año de Vida Ajustado por Calidad: revisión y Valoración Crítica de la Literatura. Minist Sanidad, Serv Soc E Igualdad Serv Evaluación Del Serv Canar La Salud. 2014;51-53.
   Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Infliximab product information; 2016. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf
   Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780–787.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:253–257.
   Web of Science ®Google Scholar
• European Medicines Agency. Humira product information; 2016. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf
   Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85–95.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2013;146:96–109.e1.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Golimumab product information; 2016. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000992/WC500052368.pdf
   Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency: Vedolizumab product information; 2016. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002782/WC500168528.pdf
   Google Scholar
• Aragón Healthcare System’s analytical accounting. 2017.
   Google Scholar
• Xie F, Blackhouse G, Assasi N, et al. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Eff Resour Alloc. 2009;7:20.
   PubMedGoogle Scholar
• Archer R, Tappenden P, Ren S, et al. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) [ID695]. Apprais Consult Doc. 2014;20:450.
   Google Scholar
• Rech G Red Hospitalaria de Costes Hospitalarios [Internet]; 2017. Available from: www.rechosp.org
   Google Scholar
• Arseneau KO, Sultan S, Provenzale DT, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? . Clin Gastroenterol Hepatol. 2006;4:1135–1142.
   PubMed Web of Science ®Google Scholar
• Somenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Mak. 1993;13:332–338.
   Web of Science ®Google Scholar
• Hoie O, Wolters FL, Riis L, et al. Disease ECSG of IB. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132(2):507–515.
   PubMed Web of Science ®Google Scholar
• Mei W-Q, Hu H-Z, Liu Y, et al. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: a meta-analysis. World J Gastroenterol. 2015;21:6044–6051.
   PubMed Web of Science ®Google Scholar
• Zhu G-Q, Zou Z-L, Zheng J-N, et al. Systematic review and network meta-analysis of randomized controlled trials: comparative effectiveness and safety of direct-acting antiviral agents for treatment-naive hepatitis C genotype 1. Medicine (Baltimore). 2016;95:e3004.
   PubMed Web of Science ®Google Scholar
• Haustein R, de Millas C, Hoer A HB. Saving money in the European healthcare systems with biosimilars. Generics Biosimilars Initiat J. 2012;1:120–126.
   Google Scholar
• Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohn’s Colitis. 2013;7:586–589.
   Google Scholar
• Longobardi T. Work losses related to inflammatory bowel disease in Canada: results from a national population health survey. Am J Gastroenterol. 2003;98:844–849.
   PubMed Web of Science ®Google Scholar
• Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol. 2003;98:1064–1072.
   PubMed Web of Science ®Google Scholar
• Wilson M, Kerrigan M, Smyth M, et al. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab for treatment of moderately-to-severely active ulcerative colitis in the United Kingdom. United Eur Gastroenterol J. 2015;1:A608.
   Google Scholar
• Cohen RD, Yu AP, Wu EQ, et al. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31:693–707.
   PubMed Web of Science ®Google Scholar
• Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn’s disease and ulcerative colitis. J Occup Env Med. 2008;50:1261–1272.
   PubMed Web of Science ®Google Scholar
• Van Der Valk ME, Mangen M-J-J, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014;63:72–79.
   PubMed Web of Science ®Google Scholar
• LeBlanc K, Mosli MH, Parker CE, et al. The impact of biological interventions for ulcerative colitis on health-related quality of life. Cochrane Database Syst Rev. 2015;9:CD008655.
   Google Scholar
• Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:1–20.
   PubMed Web of Science ®Google Scholar
• Marri SR, Buchman AL. The education and employment status of patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2005;11:171–177.
   PubMed Web of Science ®Google Scholar
• Martin S, Pan DU, Dehler S, et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009 May 15;61(5):560–568
   Google Scholar
• Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care. 2008;6:1–14.
   PubMedGoogle Scholar
• Fidder HH, Singendonk MMJ, Have MVD, et al. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol. 2013 Jul 21;19(27):4344–4350.
   Google Scholar
• Mao EJ, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 2013;45:3–13.
   Web of Science ®Google Scholar